Explore All 790 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | March 17, 2021 |
| Target | Pfizer - Biologics DS and DP Manufacturing Facilities |
| Sector | Life Science |
| Buyer(s) | WuXi Biologics |
| Sellers(s) | Pfizer |
| Deal Type | Divestiture |
FILTER BY
| Category | Company |
|---|---|
| Founded | 2014 |
| Sector | Life Science |
| Employees | 12,552 |
| Revenue | 18.7B CNY (2024) |
WuXi Biologics is an open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. WuXi Biologics was founded in 2014 and is based in Wuxi, China.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 3 |
| Sector: Life Science | 1 of 3 |
| Type: Divestiture | 1 of 2 |
| Country: China | 1 of 3 |
| Year: 2021 | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-07 |
CMAB Biopharma
Suzhou, China CMAB Biopharma is a full-service contract development and manufacturing organization (CDMO) dedicated to providing process development and manufacturing services for biologic products. The company provides bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. Its adaptable, service-oriented business enables clients to take their innovative concepts for tomorrow’s medicines from DNA to clinical products today. CMAB Biopharma was formed in 2017 and is based in Suzhou, China. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1849 |
| Sector | Life Science |
| Employees | 81,000 |
| Revenue | 63.6B USD (2024) |
Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.
| Deal Context for Seller | # |
|---|---|
| Overall | 17 of 19 |
| Sector: Life Science | 12 of 14 |
| Type: Divestiture | 14 of 15 |
| Country: China | 1 of 1 |
| Year: 2021 | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-10-22 |
Arixa Pharmaceuticals
Palo Alto, California, United States Arixa Pharmaceuticals, Inc. develops oral antibiotics for antibiotic-resistant Gram-negative infections. Arixa Pharmaceuticals is based in Palo Alto, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-04-28 |
Amplyx
San Diego, California, United States Amplyx is a provider in the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. Amplyx was founded in 2006 and is based in San Diego, California. |
Buy | - |
